Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Medacta Group

SWX:MOVE
Snowflake Description

High growth potential with adequate balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
MOVE
SWX
CHF2B
Market Cap
  1. Home
  2. CH
  3. Healthcare
Company description

Medacta Group SA, an orthopedics company, designs and produces orthopedic products. The last earnings update was 170 days ago. More info.


Add to Portfolio Compare Print
MOVE Share Price and Events
7 Day Returns
1.1%
SWX:MOVE
2.1%
CH Medical Equipment
0.2%
CH Market
1 Year Returns
-
SWX:MOVE
29.8%
CH Medical Equipment
17.6%
CH Market
MOVE Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Medacta Group (MOVE) 1.1% 5.6% 4.9% - - -
CH Medical Equipment 2.1% 4.8% 9% 29.8% 88.8% 148.4%
CH Market 0.2% 2.2% 7% 17.6% 22.9% 22.7%
1 Year Return vs Industry and Market
  • No trading data on MOVE.
  • No trading data on MOVE.
Price Volatility
Industry
5yr Volatility vs Market

MOVE Value

 Is Medacta Group undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Medacta Group to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Medacta Group.

SWX:MOVE Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 4 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 4.5%
Perpetual Growth Rate 10-Year CH Government Bond Rate -0.6%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for SWX:MOVE
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year CH Govt Bond Rate -0.6%
Equity Risk Premium S&P Global 5.4%
Medical Equipment Unlevered Beta Simply Wall St/ S&P Global 0.82
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.823 (1 + (1- 18%) (10.73%))
0.93
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.93
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= -0.55% + (0.93 * 5.44%)
4.51%

Discounted Cash Flow Calculation for SWX:MOVE using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Medacta Group is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

SWX:MOVE DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (EUR, Millions) Source Present Value
Discounted (@ 4.51%)
2020 37.50 Analyst x2 35.88
2021 48.50 Analyst x2 44.41
2022 56.41 Est @ 16.32% 49.42
2023 62.77 Est @ 11.26% 52.62
2024 67.61 Est @ 7.72% 54.23
2025 71.15 Est @ 5.24% 54.61
2026 73.64 Est @ 3.5% 54.08
2027 75.32 Est @ 2.29% 52.93
2028 76.40 Est @ 1.43% 51.38
2029 77.04 Est @ 0.84% 49.57
Present value of next 10 years cash flows €499.00
SWX:MOVE DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= €77.04 × (1 + -0.55%) ÷ (4.51% – -0.55%)
€1,514.89
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= €1,514.89 ÷ (1 + 4.51%)10
€974.75
SWX:MOVE Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= €499.00 + €974.75
€1,473.75
Equity Value per Share
(EUR)
= Total value / Shares Outstanding
= €1,473.75 / 20.00
€73.69
SWX:MOVE Discount to Share Price
Calculation Result
Exchange Rate EUR/CHF
(Reporting currency to currency of SWX:MOVE)
1.062
Value per Share
(CHF)
= Value per Share in EUR x Exchange Rate (EUR/CHF)
= €73.69 x 1.062
CHF78.25
Value per share (CHF) From above. CHF78.25
Current discount Discount to share price of CHF82.90
= -1 x (CHF82.90 - CHF78.25) / CHF78.25
-5.9%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of Medacta Group is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Medacta Group's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Medacta Group's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
SWX:MOVE PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-06-30) in EUR €1.10
SWX:MOVE Share Price ** SWX (2020-02-19) in CHF CHF82.9
SWX:MOVE Share Price converted to EUR reporting currency Exchange rate (CHF/ EUR) 0.942 €78.07
Switzerland Medical Equipment Industry PE Ratio Median Figure of 7 Publicly-Listed Medical Equipment Companies 54.16x
Switzerland Market PE Ratio Median Figure of 170 Publicly-Listed Companies 21.28x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Medacta Group.

SWX:MOVE PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= SWX:MOVE Share Price ÷ EPS (both in EUR)

= 78.07 ÷ 1.10

71.27x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Medacta Group is overvalued based on earnings compared to the CH Medical Equipment industry average.
  • Medacta Group is overvalued based on earnings compared to the Switzerland market.
Price based on expected Growth
Does Medacta Group's expected growth come at a high price?
Raw Data
SWX:MOVE PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 71.27x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts
23.9%per year
Switzerland Medical Equipment Industry PEG Ratio Median Figure of 6 Publicly-Listed Medical Equipment Companies 3.02x
Switzerland Market PEG Ratio Median Figure of 123 Publicly-Listed Companies 2.09x

*Line of best fit is calculated by linear regression .

SWX:MOVE PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 71.27x ÷ 23.9%

2.99x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Medacta Group is poor value based on expected growth next year.
Price based on value of assets
What value do investors place on Medacta Group's assets?
Raw Data
SWX:MOVE PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-06-30) in EUR €5.27
SWX:MOVE Share Price * SWX (2020-02-19) in CHF CHF82.9
SWX:MOVE Share Price converted to EUR reporting currency Exchange rate (CHF/ EUR) 0.942 €78.07
Switzerland Medical Equipment Industry PB Ratio Median Figure of 9 Publicly-Listed Medical Equipment Companies 6.83x
Switzerland Market PB Ratio Median Figure of 215 Publicly-Listed Companies 1.79x
SWX:MOVE PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= SWX:MOVE Share Price ÷ Book Value per Share (both in EUR)

= 78.07 ÷ 5.27

14.81x

* Primary Listing of Medacta Group.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Medacta Group is overvalued based on assets compared to the CH Medical Equipment industry average.
X
Value checks
We assess Medacta Group's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Medical Equipment industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Medical Equipment industry average (and greater than 0)? (1 check)
  5. Medacta Group has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

MOVE Future Performance

 How is Medacta Group expected to perform in the next 1 to 3 years based on estimates from 4 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
23.9%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Medacta Group expected to grow at an attractive rate?
  • Medacta Group's earnings growth is expected to exceed the low risk savings rate of -0.6%.
Growth vs Market Checks
  • Medacta Group's earnings growth is expected to exceed the Switzerland market average.
  • Medacta Group's revenue growth is expected to exceed the Switzerland market average.
Annual Growth Rates Comparison
Raw Data
SWX:MOVE Future Growth Rates Data Sources
Data Point Source Value (per year)
SWX:MOVE Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts 23.9%
SWX:MOVE Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 4 Analysts 11%
Switzerland Medical Equipment Industry Earnings Growth Rate Market Cap Weighted Average 44.4%
Switzerland Medical Equipment Industry Revenue Growth Rate Market Cap Weighted Average 7.1%
Switzerland Market Earnings Growth Rate Market Cap Weighted Average 10.5%
Switzerland Market Revenue Growth Rate Market Cap Weighted Average 3.4%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
SWX:MOVE Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (7 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
All numbers in EUR Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
SWX:MOVE Future Estimates Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 536 1
2023-12-31 486 1
2022-12-31 434 112 73 1
2021-12-31 389 94 63 4
2020-12-31 348 80 55 4
2020-02-19
2019-12-31 309 50 35 4
SWX:MOVE Past Financials Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income *
2019-06-30 291 50 33
2019-03-31 282 58 39
2018-12-31 273 66 46
2017-12-31 245 52 33
2016-12-31 219 56 39

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Medacta Group's earnings are expected to grow significantly at over 20% yearly.
  • Medacta Group's revenue is expected to grow by 11% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
SWX:MOVE Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (7 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below

All data from Medacta Group Company Filings, last reported 7 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

SWX:MOVE Future Estimates Data
Date (Data in EUR Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31
2021-12-31 3.14 3.15 3.14 3.00
2020-12-31 2.77 2.78 2.74 3.00
2020-02-19
2019-12-31 1.80 1.87 1.68 3.00
SWX:MOVE Past Financials Data
Date (Data in EUR Millions) EPS *
2019-06-30 1.10
2019-03-31 1.57
2018-12-31 2.29
2017-12-31 837.07
2016-12-31 980.08

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Medacta Group is expected to make outstanding use of shareholders’ funds in the future (Return on Equity greater than 40%).
X
Future performance checks
We assess Medacta Group's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Switzerland market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Switzerland market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Medacta Group has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

MOVE Past Performance

  How has Medacta Group performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Medacta Group's growth in the last year to its industry (Medical Equipment).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Insufficient data to establish if Medacta Group's year on year earnings growth rate was positive over the past 5 years.
  • Medacta Group's 1-year earnings growth is negative, it can't be compared to the 5-year average.
  • Medacta Group's 1-year earnings growth is negative, it can't be compared to the CH Medical Equipment industry average.
Earnings and Revenue History
Medacta Group's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Medacta Group Company Filings, last reported 7 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

SWX:MOVE Past Revenue, Cash Flow and Net Income Data
Date (Data in EUR Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-06-30 290.98 32.84 146.23 5.20
2019-03-31 281.79 39.30 141.97 4.57
2018-12-31 272.61 45.75 137.71 3.93
2017-12-31 244.68 33.50 128.80 3.06
2016-12-31 219.05 39.22 112.99 2.67

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Whilst Medacta Group has efficiently used shareholders’ funds last year (Return on Equity greater than 20%), this is metric is skewed due to its high level of debt.
  • Medacta Group used its assets less efficiently than the CH Medical Equipment industry average last year based on Return on Assets.
  • Unable to establish if Medacta Group improved its use of capital last year versus 3 years ago (Return on Capital Employed) due to insufficient past data.
X
Past performance checks
We assess Medacta Group's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Medical Equipment industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Medacta Group has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

MOVE Health

 How is Medacta Group's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Medacta Group's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Medacta Group is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Medacta Group's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Medacta Group's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 1.2x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Medacta Group Company Filings, last reported 7 months ago.

SWX:MOVE Past Debt and Equity Data
Date (Data in EUR Millions) Total Equity Total Debt Cash & Short Term Investments
2019-06-30 105.43 148.76 19.57
2019-03-31 105.43 148.76 19.57
2018-12-31 89.07 155.74 33.71
2017-12-31 101.67 89.89 25.12
2016-12-31 146.87 32.75 20.71
  • Medacta Group's level of debt (141.1%) compared to net worth is high (greater than 40%).
  • Unable to establish if Medacta Group's debt level has increased without past 5-year debt data.
  • Debt is well covered by operating cash flow (33.6%, greater than 20% of total debt).
  • Interest payments on debt are well covered by earnings (EBIT is 28.3x coverage).
X
Financial health checks
We assess Medacta Group's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Medacta Group has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

MOVE Dividends

 What is Medacta Group's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Medacta Group dividends. Estimated to be 0.99% next year.
If you bought CHF2,000 of Medacta Group shares you are expected to receive CHF0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Medacta Group's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Medacta Group's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
SWX:MOVE Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
Switzerland Medical Equipment Industry Average Dividend Yield Market Cap Weighted Average of 5 Stocks 0.9%
Switzerland Market Average Dividend Yield Market Cap Weighted Average of 163 Stocks 2.8%
Switzerland Minimum Threshold Dividend Yield 10th Percentile 1.1%
Switzerland Bottom 25% Dividend Yield 25th Percentile 1.7%
Switzerland Top 25% Dividend Yield 75th Percentile 3.4%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

SWX:MOVE Future Dividends Estimate Data
Date (Data in €) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31
2021-12-31 0.83 4.00
2020-12-31 0.71 4.00
2020-02-19
2019-12-31 0.46 4.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Medacta Group has not reported any payouts.
  • Unable to verify if Medacta Group's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Medacta Group's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Medacta Group has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Medacta Group's dividends in 3 years as they are not expected to pay a notable one for Switzerland.
X
Income/ dividend checks
We assess Medacta Group's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Medacta Group afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Medacta Group has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

MOVE Management

 What is the CEO of Medacta Group's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Francesco Siccardi
TENURE AS CEO 1.3 years
CEO Bio

Dr. Francesco Siccardi, Sr. founded Medacta International SA and has been its Chief Executive Officer since November 1, 2018. Dr. Siccardi served as an Executive Vice President of Medacta International SA from 2010 to November 1, 2018. Dr. Francesco founded Bieffe Biochimici Firenze in 1958. A biomechanical engineer by training, he has been instrumental in the conception, development, and manufacture of many of Medacta’s leading products, including the AMIS® (Anterior Minimally Invasive Surgery) product line for total hip replacement, GMK® Sphere Total Knee System, MyKnee® Patient-Matched Technology, Efficiency Single Use Instruments, and the recently launched Medacta Shoulder System. Additionally, he was the driving force behind the creation of the Medacta Spine and Sports Medicine divisions. Francesco Siccardi joined Medacta in 2002 after studying Biomedical Engineering at the Politecnico of Milan.

CEO Compensation
  • Insufficient data for Francesco to compare compensation growth.
  • Insufficient data for Francesco to establish whether their remuneration is reasonable compared to companies of similar size in Switzerland.
Management Team

Francesco Siccardi

TITLE
Founder & CEO
TENURE
1.3 yrs

Alberto Siccardi

TITLE
President

Alessandro Siccardi

TITLE
Head of Supply Chain & Director
Board of Directors

Alessandro Siccardi

TITLE
Head of Supply Chain & Director

Maria Siccardi

TITLE
Director
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (CHF) Value (CHF)
X
Management checks
We assess Medacta Group's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Medacta Group has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

MOVE News

Simply Wall St News

MOVE Company Info

Description

Medacta Group SA, an orthopedics company, designs and produces orthopedic products. It offers personalized kinematic models and 3D planning tools for use in hip, knee, shoulder, and spine procedures. The company was founded in 1958 and is headquartered in Castel San Pietro, Switzerland.

Details
Name: Medacta Group SA
MOVE
Exchange: SWX
Founded: 1958
CHF1,658,000,000
20,000,000
Website: http://www.medacta.com
Address: Medacta Group SA
Strada Regina,
Castel San Pietro,
Ticino, 6874,
Switzerland
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
SWX MOVE Register Shares SIX Swiss Exchange CH CHF 03. Apr 2019
OTCPK MEDG.F Register Shares Pink Sheets LLC US USD 03. Apr 2019
DB 6MD Register Shares Deutsche Boerse AG DE EUR 03. Apr 2019
LSE 0A05 Register Shares London Stock Exchange GB CHF 03. Apr 2019
Number of employees
Current staff
Staff numbers
1,041
Medacta Group employees.
Industry
Health Care Equipment
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/02/19 23:35
End of day share price update: 2020/02/19 00:00
Last estimates confirmation: 2020/01/29
Last earnings filing: 2019/09/02
Last earnings reported: 2019/06/30
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.